Core Viewpoint - Heng Rui Medicine (600276.SH) emphasizes a differentiated research and development strategy focused on clinical needs, leveraging advanced technology platforms to create a matrix of differentiated innovative products [1] Group 1: Product Development - The company has developed the first-in-class innovative drug, Ruilafup α injection, which was approved for domestic market launch in January 2026, marking it as the world's first approved PD-L1/TGF-βRII bispecific antibody fusion protein [1] - There are over 100 self-innovated products currently in clinical development, including those with potential for first-in-class or best-in-class status [1] Group 2: Future Strategy - The company plans to continue exploring cutting-edge international drug targets that have potential for first-in-class or best-in-class innovations, aiming to continuously produce differentiated and competitively innovative products [1]

Group 1 - The core viewpoint of the article is that Heng Rui Pharmaceutical has established a financial shared service center to enhance its financial management through digital and intelligent technologies [1] Group 2 - The company aims to improve the standardization, centralization, refinement, and intelligence of its financial management [1]

Group 1 - The core viewpoint of the article is that Heng Rui Pharmaceutical is actively monitoring technological advancements in the industry and exploring their auxiliary applications in drug development [1] Group 2 - The company is engaging with investors through interactive platforms to address inquiries regarding its focus on technology [1]

Core Viewpoint - Heng Rui Medicine emphasizes its commitment to technological innovation and international development strategies to ensure sustainable growth and better returns for shareholders [1] Group 1 - The company is actively pursuing a share buyback program as per its established plan [1]

Group 1 - Unisplendour plans to raise no more than 5.57 billion yuan through a private placement to acquire a 6.98% stake in H3C and for other projects [1] - Dawi Technology's Zhangbei data center project will not involve computing power leasing and is expected to have minimal revenue contribution in 2025 [2] - Kaixin Network's subsidiary signed a settlement agreement with Legend IP, which is expected to positively impact the company's profit by approximately 200 million yuan [3] Group 2 - Newray plans to acquire a 70% stake in PCB tool company Huilian Electronics for no more than 700 million yuan, enhancing its market position [4] - Shangwei New Materials' embodied intelligent robot business is still in the product development stage and has not yet generated revenue [5] - Lanshi Heavy Industry's deputy general manager is under investigation for suspected violations, but the company's operations remain unaffected [6] Group 3 - Tianji Technology is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations, but its operations are normal [8] - Top Group expects a net profit decline of 3% to 13% in 2025, despite revenue growth of 8.08% to 14.10% [9] - Shoulu Hotel's subsidiary plans to invest 281 million yuan in a new hotel property project, expected to enhance its business scale and profitability [10] Group 4 - Pingzhi Information plans to raise no more than 1 billion yuan for the construction of a domestic intelligent computing center [11] - Dongfang Guoxin's Inner Mongolia intelligent computing center project has been partially completed, contributing a small revenue share [12] - Zhongwei Semiconductor intends to allocate 1 billion yuan of surplus fundraising for a new investment project [13] Group 5 - Guolin Technology plans to issue up to 16.5 million shares, which will increase its total share capital to 201 million shares [14] - Dabeinong reported a 22.71% year-on-year increase in pig sales in January [15] - Qiu Tai Technology sold 41.48 million mobile camera modules in January, a 19.5% year-on-year increase [19]

（文章来源：证券日报） 证券日报网讯 2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临 床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。例如，公司自主研发的1类创新药瑞拉 芙普α注射液已于2026年1月在国内获批上市，是全球首款获批上市的抗PD-L1/TGF-βRII双特异性抗体 融合蛋白；公司还有100多个自主创新产品正在临床开发，其中不乏具有同类首创/同类最佳潜力的产 品。公司未来还将继续积极探索国际前沿的、具有同类首创或同类最佳潜力的药物靶点，不断产出差异 化、具有创新竞争力的产品。 ...

北京商报讯（记者 王寅浩 宋雨盈）2月11日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有 限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入突破性治疗品 种名单，这是瑞康曲妥珠单抗第10项获得突破性治疗认证的适应症。 公告显示，恒瑞医药注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2激活 突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌成人患者。 ...

证券日报网讯2月11日，恒瑞医药（600276）在互动平台回答投资者提问时表示，公司2025年利润分配 方案尚未披露，敬请关注公司后续于交易所网站上发布的相关公告。 ...

拟定适应症(或功能主治)：HER2(ERBB2)激活突变的局部晚期或转移性非小细胞肺癌患者的一线治疗。 智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日,公司子公司苏州盛迪亚生物医药有限公司的注 射用瑞康曲妥珠单抗(SHR-A1811)被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，这是 瑞康曲妥珠单抗第10项获得突破性治疗认证的适应症。 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation from the National Medical Products Administration for its injectable SHR-A1811, marking the 10th indication for this drug [1] Group 1 - The proposed indication for SHR-A1811 is as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations [1] - SHR-A1811 is expected to be approved for domestic market launch in May 2025, targeting adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy [1]